901771-45-7

Basic information

• Product Name: 1H-Thieno[3,4-c]pyrazol-3-amine,4,6-dihydro-(9CI)
• Synonyms: 1H-Thieno[3,4-c]pyrazol-3-amine,4,6-dihydro-(9CI);4,6-dihydro-1H-Thieno[3,4-c]pyrazol-3-amine
• CAS NO: 901771-45-7
• Molecular Formula: C₅H₇N₃S
• Molecular Weight: 141.197
• Product Categories: VARIOUSAMINE
• Mol File: 901771-45-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Thieno[3,4-c]pyrazol-3-amine,4,6-dihydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Thieno[3,4-c]pyrazol-3-amine,4,6-dihydro-(9CI)(901771-45-7)
• EPA Substance Registry System: 1H-Thieno[3,4-c]pyrazol-3-amine,4,6-dihydro-(9CI)(901771-45-7)

Safety Data

• Hazardous Substances Data: 901771-45-7(Hazardous Substances Data)

Usage

Structure

A derivative of thieno[3,4-c]pyrazole with an amine group at position 3 and a dihydro group at positions 4 and 6

Potential applications

Pharmaceutical research (modulation of biological targets, interaction with enzymes and receptors)

Use as a building block

In the synthesis of other organic compounds

Interesting target

For further study and development due to its properties and potential uses

Upstream product

• 16563-14-7 4-oxotetrahydrothiophene-3-carbonitrile 
• 302-01-2 hydrazine 

Downstream Products

• 901771-53-7 4-amino-2-mesityl-7H,9H-thieno[3',4':3,4]pyrazolo[1,5-a]pyrimidine-3-carbonitrile 

Relevant articles and documents

5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS

The present invention relates to compounds of formula (I) and the use of these compounds as pharmaceuticals, e.g. in preventing or treating a CXCR2 receptor mediated condition or disease.

BICYCLIC PYRIMIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted bicyclic pyrimidines which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.